Rius Medical

Dear investors,

Most promising candidates in late-stage development have poor commercial outcome due to inability to scale up development.

On January 2022 Anokion announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease www and has ongoing March 2021 initiated Patient Dosing in Phase 1 Trial of ANK-700 for the treatment of Multiple Sclerosis. Anokion’s founding platform uses red blood cells as Trojan horses for delivering autoantigens to immune cells in a way that induced tolerance - to fight autoimmune diseases.

The upgrade in “scale up development” has Rius Medical simplifying tolerance-inducing autoantigens promising candidates by overthrowing traditional production models in favour of a new model with synthetic biology, genetic engineering and stem cells combine for automation.

Traditional production models have all the cells made by hand in batches, by highly trained scientists sitting in a clean room. That’s not scalable. Rius Medical solving the scalability problem in cell therapy, implements Yamanaka’s discovery in 2006 that opened the way for cell reprogramming. Rather than mimicking the slow natural process of cell culture in cell therapy, Rius Medical triggers specific genes in cells to change how they grow, making the scalability process faster. This approach includes both automation via “cell lines candidates self-renewal” as 1995 defined by Keith Humphries HoxB4 self renewal of haematopoietic stem cells and cell “self-encapsulation” of therapeutic cargo - a unique selling proposition among cell reprogramming startups.

If you as an investor have the fear of missing out on the revolutionary approach, one where venture capital investors and potential pharma partners reveal “a growing interest in the field about cell reprogramming www, then a business partnership with Rius Medical delivers on simplifying these complex therapies.

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Keep in mind that you the investor in Rius Medical shall receive 20% refund on investment from the German Ministry for Economic Affairs and Climate Protection (BMWK) www. Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases such as type 1 diabetes by solving the problem of drug delivery through stem cell reprogramming.

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO

Email: denisdemarais@riusmedical.de

Dear investors,

Advanced manufacturing is the use of knowledge and innovative technology to produce complex products. The involvement of regulatory T cells (Tregs) in amyotrophic lateral sclerosis and their therapeutic potential are now considered a promising therapeutic target for neuroprotection in ALS www. Because Harvey Lodish of Massachusetts Institute of Technology and colleagues implemented immune tolerance with red blood cells delivery of protein therapeutics in mouse model of multiple sclerosis and of type 1 diabetes www, thus firmly linking fighting inflammation to fighting Ageing, amyotrophic lateral sclerosis (ALS) and Regulatory T cells therapeutic is at the back of my mind.

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease or Lou Gehrig's disease, is a neurodegenerative disease that results in the progressive loss of motor neurons that control voluntary muscles. ALS is the most common type of motor neuron disease - think of astrophysicist Stephen Hawking.

Allogeneic cell therapies (CAR NK and encapsulated RBC) under a unique platform technology by my company Rius Medical combine synthetic biology, genetic engineering and stem cells for automation. This enabling technology platform / Advanced manufacturing by Rius Medical has the potential to transform the cell and gene therapy ecosystem and deliver the promise of cell and gene therapy to impact patients’ lives.

Rius Medical brings the best people with the best ideas who are working to make that happen. Rius Medical developing Advanced Manufacturing disrupts the biopharmaceutical industry by overthrowing traditional production models in favour of a new model with synthetic biology, genetic engineering and stem cells combine for automation! Traditional production models have all the cells made by hand in batches, by highly trained scientists sitting in a clean room. That’s not scalable. Rius Medical solving the scalability problem in cell therapy, implements Yamanaka’s discovery in 2006 that opened the way for cell reprogramming. Rather than mimicking the slow natural process of cell culture in cell therapy, Rius Medical triggers specific genes in cells to change how they grow, making the scalability process faster. This approach includes both automation and cell encapsulation of therapeutic cargo - a unique selling proposition among cell reprogramming startups.

Rius Medical technology for Advanced Manufacturing cuts out many labour-intensive steps from the process and speeds up cell production. Cell reprogramming represents a paradigm shift in the way we view biology. Cell reprogramming is an example of synthetic biology, which basically means taking a ‘software’ approach to biology. Rius Medical’s DNA quaternary coding is like Microsoft’s Windows operating system on stem cells! This gives Rius Medical a higher success than traditional methods such as Cambridge USA Rubius Therapeutics with stem cell-derived cell therapies for drug delivery www.

If you as an investor have the fear of missing out on the revolutionary approach, one where venture capital investors and potential pharma partners reveal “a growing interest in the field about cell reprogramming www, then a business partnership with Rius Medical delivers on simplifying these complex therapies.

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Keep in mind that you the investor in Rius Medical shall receive 20% refund on investment from the German Ministry for Economic Affairs and Climate Protection (BMWK). Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases such as type 1 diabetes by solving the problem of drug delivery through stem cell reprogramming.

Many thanks and warmest regards,

Denis

Denis Demarais

Founder and CEO

Email: denisdemarais@riusmedical.de

Dear investors,

[1] Bpifrance Large Venture September 2021 financing round of TreeFrog Therapeutics www is another example of providing stem cell-derived cell therapies for millions. As investors gain increased level of expertise and competencies on technologies from cell therapy developers, investors funding and confidence increase. Thus making 2021 for Cell and gene therapy developers globally as an all-time annual record for funding at 23.1 billion US dollar www.

The manufacture of these complex therapies, i.e. cell therapies, is a big bottleneck that many startups aim to tackle. TreeFrog Therapeutics is the latest in a thriving movement to make the manufacture of gene and cell therapies easier and cheaper www. Experts acknowledge that <<research alone cannot get these complex treatments to patients. “The sharp discrepancy between the high number of products in early-stage development and the still very small number that have made it onto the market, as well as their cost, speaks to the impact and importance of cost-effective and scalable manufacturing,”>>.

Many biotech companies – like Rius Medical in Germany, are working to make cell therapy production cheaper and faster. The UK-based bit.bio is one of several working on cell reprogramming, a method for efficiently converting stem cells into a desired cell type. TreeFrog Therapeutics in France raised a €64M Series B round in September 2021 to fund technology boosting cell therapy yield by coating fragile cells in a protective shell www.

[2] The field of cell reprogramming www is not limited to induced pluripotent stem cells (iPSCs) stem cells. Slow and inefficient cell manufacturing techniques hamper traditional life sciences research and cell therapy development. Another challenge slowing the growth of cell and gene therapy manufacturing is a lack of skilled staff. A number of cell therapy firms including Orgenesis in the US are investing in automation to work around the problem.

Rius Medical brings the best people with the best ideas who are working to make that happen. Rius Medical developing Advanced Manufacturing disrupts the biopharmaceutical industry by overthrowing traditional production models in favour of a new model with synthetic biology, genetic engineering and stem cells combine for automation!

If you as an investor have the fear of missing out on the revolutionary approach, one where venture capital investors and potential pharma partners reveal “a growing interest in the field about cell reprogramming www, then a business partnership with Rius Medical delivers on simplifying these complex therapies.

To the obstacles in obtaining enough cells and transporting them between centers, leading to long waits and high prices for the cell therapy, solution industry-oriented, Rius Medical provides optimal support for (1) enzyme delivery encapsulated red blood cells (2) antigen delivery encapsulated red blood cells and (3) natural killer cells immuno oncology on ONE-Platform technology with synthetic biology, genetic engineering and stem cells combine for automation!

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Keep in mind that you the investor in Rius Medical shall receive 20% refund on investment from the German Ministry for Economic Affairs and Climate Protection (BMWK). Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases such as type 1 diabetes by solving the problem of drug delivery through stem cell reprogramming.

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO

Email: denisdemarais@riusmedical.de

Dear investors,

[1] Seeking a lead investor EUR 500,000 Equity Capital to a business angel EUR 50,000 Equity Capital is what Rius Medical is doing alongside the EUR 110,000 Grant money from the German Ministry for Economic Affairs and Climate Protection (BMWK) and EUR 450,000 Grant money from the state of Baden Württemberg Invest BW Innovation funding program through funds from EU’s European Regional Development Fund (ERDF). Essentially investors get a 20% refund on their investment in Rius Medical via BMWK www!

[2] In doing BIOLOGICS Drug Discovery, a sector ripe for change is Drug Delivery. Rius Medical brings the best people with the best ideas who are working to make that happen. Yes Rius Medical developing Advanced Manufacturing disrupts the biopharmaceutical industry by overthrowing traditional production models in favour of a new model with synthetic biology, genetic engineering and stem cells combine.

The novel scientific discovery behind Rius Medical is DNA/quaternary code design!

To be clear, Rius Medical is developing Advanced Manufacturing by reprogramming stem cells as a mammalian expression system for recombinant plasma proteins therapeutics with excess cells that mature as needed into desired drug-loaded, cargo-carrying red blood cells. This is the B2B service resulting from the innovation project of Rius Medical. Rius Medical offers reprogramming of stem cells as a service, similar to contract manufacturing, only as a one-off production. Solution industry-oriented, Rius Medical provides optimal support for customer-specific production and facilitates the way of working with this type of one-off production service. Rius Medical’s DNA quaternary coding is like Microsoft’s Windows operating system on stem cells!

That has immediate application in enzyme replacement therapies, to provide life-changing therapies for people with rare diseases and for people with severe forms of cancer. Meaning EXIT-opportunity for investors with Rius Medical Technology transfer deals to [1] FR, Erytech Pharma (Enzyme L-Asparaginase) in the fight against cancer: i.e. Leukaemia, pancreatic cancer and breast cancer - improving the productivity, profitability, and safety through the application of engineering and manufacturing technology - i.e. INNOVATION and [2] USA, Travere Therapeutics parent company of CH, Orphan Technologies (Enzyme Thymidine phosphorylase) by December 2023.

The mission of Rius Medical is to fully automate cell and gene therapy (CGT) manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of life-saving treatments. All through one Platform technology for multiple cell-based therapies/assets as stem cells derived cargo carrying red blood cells inclusive therapeutic protein as innovation to blood-donation derived empty red blood cells.

When fighting cancer strongly appeals to you at the core, a business partnership with Rius Medical delivers on cancer patients having less frequent administration of “L-Asparaginase medicine”, requiring very fewer visits to daycare, and is therefore more patient-friendly. A significant improvement in drug delivery with 120 days / i.e. 4 months to commercially available 20 hours if not 7 days “L-Asparaginase medicine” enzyme activity!

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases such as type 1 diabetes by solving the problem of drug delivery through stem cell reprogramming.

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO

Email: denisdemarais@riusmedical.de